Provided by Tiger Trade Technology Pte. Ltd.

Amphastar Pharmaceuticals

19.01
-0.5200-2.66%
Post-market: 19.010.00000.00%19:59 EDT
Volume:346.02K
Turnover:6.67M
Market Cap:862.49M
PE:9.36
High:19.64
Open:19.37
Low:18.92
Close:19.53
52wk High:31.26
52wk Low:17.03
Shares:45.37M
Float Shares:34.22M
Volume Ratio:0.67
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):2.03
ROE:12.90%
ROA:6.37%
PB:1.09
PE(LYR):9.36

Loading ...

Sector Update: Health Care Stocks Advance Pre-Bell Monday

MT Newswires Live
·
Dec 15, 2025

Amphastar Pharmaceuticals Says FDA Approved Teriparatide Injection as Osteoporosis Treatment

MT Newswires Live
·
Dec 15, 2025

Amphastar Pharmaceuticals: FDA Determined That Co's Teriparatide Is Bioequivalent & Therapeutically Equivalent to Eli Lilly's Forteo

THOMSON REUTERS
·
Dec 15, 2025

Amphastar Pharmaceuticals Inc: FDA Approval for Teriparatide Injection

THOMSON REUTERS
·
Dec 15, 2025

FDA Approves Amphastar's Teriparatide Prefilled Pen for Osteoporosis

Reuters
·
Dec 15, 2025

Is Amphastar Pharmaceuticals Mispriced After a Tough Year and Promising Cash Flow Outlook in 2025?

Simply Wall St.
·
Dec 10, 2025

Amphastar Pharmaceuticals Initiated at Equal-Weight by Barclays

Dow Jones
·
Dec 09, 2025

Barclays Initiates Amphastar Pharmaceuticals at Equalweight With $30 Price Target

MT Newswires Live
·
Dec 09, 2025

Amphastar Pharmaceuticals Inc : Barclays Initiates Coverage With Equal Weight Rating; Target Price $30

THOMSON REUTERS
·
Dec 09, 2025

U.S. RESEARCH ROUNDUP-AstraZeneca, Confluent, Pepsico

Reuters
·
Dec 09, 2025

Amphastar Pharmaceuticals Director Richard K. Prins Reports Disposal of Common Shares

Reuters
·
Nov 26, 2025

Amphastar Pharmaceuticals Executives to Join Analyst-Moderated Fireside Chat at Piper Sandler Healthcare Conference

Reuters
·
Nov 24, 2025

Amphastar Pharmaceuticals reports Q2 net revenues of $174.4 million and net income of $31.0 million

Reuters
·
Nov 21, 2025

Director Floyd F. Petersen Reports Disposal of Amphastar Pharmaceuticals Common Shares

Reuters
·
Nov 18, 2025

Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Surge

Simply Wall St.
·
Nov 14, 2025

Amphastar Pharmaceuticals to Present at Jefferies Global Healthcare Conference

Reuters
·
Nov 12, 2025

Amphastar Pharmaceuticals’ Resilient Q3 2025 Earnings Call

TIPRANKS
·
Nov 11, 2025

Amphastar Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Nov 07, 2025

Amphastar Pharmaceuticals Q3 revenue beats estimates

Reuters
·
Nov 07, 2025

Amphastar Pharma Q3 Adj. EPS $0.93 Beats $0.85 Estimate, Sales $191.840M Beat $184.728M Estimate

Benzinga
·
Nov 07, 2025